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Background: Serum bile acids (SBAs) are frequently measured in dogs. However,
there is limited data comparing SBAs in different liver diseases diagnosed according
to standardized histological criteria.
Objectives: To compare resting and postprandial SBAs, and determine their sensitiv-
ity and specificity, for various liver diseases in dogs.
Animals: Three hundred and forty-one client-owned dogs with suspected liver dis-
ease that had a liver biopsy and SBAs measured.
Methods: Multicenter retrospective study. Cases were classified according to stan-
dardized histological criteria. The sensitivity and specificity of resting and postpran-
dial SBAs for the diagnosis of each liver disease, and all liver diseases combined, were
calculated.
Results: The median resting SBAs were highest in dogs with cirrhosis (98.8 μmol/L;
range, 6-135) and congenital circulatory anomalies (CCa; 79.45 μmol/L; 0.3-705). The
highest median postprandial concentrations were found in CCa (126 μmol/L; 0-726)
and chronic hepatitis (CH; 54.3 μmol/L; 0-260). Using the cut-off value of 10 μmol/L,
the highest sensitivities of resting SBAs were recorded in dogs with CCa (87.5%; 95%
confidence interval, 76.8-94.4) and CH (81.1%; 71.5-88.6). The sensitivities of post-
prandial SBAs were the highest in cholangitis (100%; 47.8-100.0) and CCa (91.1%;
78.8-97.5). The specificities of resting and postprandial SBAs for all diseases were
49.3% (37.6-61.1) and 29.7% (15.9-47.0), respectively.
Abbreviations: AH, acute hepatitis; AUC, area under the ROC curve; CCa, congenital circulatory anomalies; CH, chronic hepatitis; CI, confidence interval; cPSS, congenital portosystemic shunt;
EHPSS, extrahepatic portosystemic shunt; IHPSS, intrahepatic portosystemic shunt; M : F, male to female; PPVH, primary portal vein hypoplasia; RH, nonspecific reactive hepatitis; RHI,
reversible hepatocytic injury; ROC, receiver operating characteristic; SBA, serum bile acid; WSAVA, World Small Animal Veterinary Association.
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Conclusions and Clinical Importance: Postprandial SBAs are more sensitive but less
specific than resting SBAs for the diagnosis of liver disease. There were dogs in all
categories of liver disease with resting SBAs <10 and >90 μmol/L. Therefore, careful
interpretation of both normal and elevated values is required.
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1 | INTRODUCTION
Serum bile acids (SBAs) are increased in dogs for 3 reasons. First, if
liver function is reduced there is a decreased clearance of bile acids
from the portal circulation. Second, abnormal blood flow, such as
occurs in a portosystemic shunt, results in bile acids bypassing the
liver and therefore not being extracted by the hepatocytes. Finally,
SBAs are increased when there is an impairment of excretion as a
consequence of bile stasis.1 Measurement of postprandial SBA con-
centrations is a more sensitive marker than resting SBAs concentra-
tion for the diagnosis of liver disease.2
In 2006 the World Small Animal Veterinary Association's
(WSAVA) Liver Standardization Group produced a unified nomencla-
ture for the histologic diagnosis of liver diseases in dogs.3 These
guidelines classify liver diseases morphologically into circulatory, bili-
ary, parenchymal or neoplastic disorders. Circulatory disorders are
divided into congenital circulatory anomalies (CCa) and disorders
associated with outflow (hepatic congestion), or with portal hyperten-
sion. Within biliary tract diseases, there are subcategories for chole-
stasis and cholatestasis, biliary cystic disease and biliary atresia,
cholangitis, and diseases of the gallbladder. Parenchymal disorders
comprise reversible hepatocytic injury, which includes hepatocellular
steatosis, steroid-induced hepatopathy and cloudy swelling, hepatic
amyloidosis, hepatocellular death and inflammatory hepatopathies,
hepatic abscesses and granulomas, hepatic metabolic storage diseases
and miscellaneous disorders. Finally, the neoplastic group is composed
of all benign and malignant primary liver neoplasms, and also nodular
hyperplasia and metastatic neoplasia.3
Despite the fact that concentrations of SBAs are measured fre-
quently in dogs, there is limited data on their ability to differentiate
between different causes of liver disease. Moreover, little data exists to
determine the sensitivity and specificity of SBAs for the diagnosis of
individual diseases according to WSAVA histological criteria. Using non-
standardized histological criteria, previous studies reported that resting
and postprandial SBA concentrations had a sensitivity of greater than
65% for the diagnosis of different liver diseases.2,4 In addition, resting
and postprandial SBA concentrations greater than 30 μmol/L had speci-
ficities greater than 90% for the diagnosis of liver disease in dogs.2,5
The aims of this study were, therefore, (a) to compare resting and
postprandial SBA concentrations in different liver diseases in dogs,
and (b) to assess the sensitivity and specificity of these tests for differ-
ent liver diseases classified according to the WSAVA classification
system.
2 | MATERIALS AND METHODS
2.1 | Study design and case selection
Records of dogs which had liver tissues submitted for histological
evaluation, and the concurrent measurement of SBA concentrations
(within 7 days of histological biopsy), between September 2008 and
September 2015 at 5 referral veterinary centers in the United King-
dom (Queen's Veterinary School Hospital, Pride Veterinary Centre,
Anderson Moores Veterinary Specialists, Dick White Referrals and
Davies Veterinary Specialists) were retrospectively reviewed. All his-
tology samples were assessed by at least 1 board-certified patholo-
gist. Details recorded included age, sex, concentrations of resting and
postprandial SBAs, histological description, histological diagnosis and
additional comments made by board-certified pathologists. Dogs that
had a liver biopsy collected more than 1 week after measurement of
SBAs were excluded.
Ethical approval was granted from the School of Veterinary Medi-
cine and Science, University of Nottingham, UK, Clinical Ethical
Review panel (reference 1610151103).
2.2 | Histological classification
The histological diagnosis was used to group cases according to
WSAVA histological criteria for liver diseases in dogs using the 4 main
morphological groups of vascular, biliary, parenchymal and neoplastic
disorders.3 Cases were classified into acute hepatitis (AH), cholangitis,
chronic hepatitis (CH), CCa, cirrhosis, miscellaneous, neoplasia, non-
specific reactive hepatitis (RH), or reversible hepatocytic injury (RHI).
Dogs that had a histological diagnosis of cholangiohepatitis were
placed into the cholangitis group unless there was evidence that the
initial insult started in the hepatic parenchyma based on the com-
ments by the histopathologist. Dogs that had histological features of
more than 1 disease were placed into a single group which the pathol-
ogist stated to be the major disease.
Cases were excluded when the histological diagnosis was unclear,
or when the diagnosis did not fit with WSAVA criteria. Dogs with
obstructive cholelithiasis were also removed from the study, as the
obstruction would have affected the SBAs concentrations, regardless
of the histological changes present in the liver.
Dogs with different types of CCa, which included extrahepatic
portosystemic shunt (EHPSS), intrahepatic portosystemic shunt
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(IHPSS), primary portal vein hypoplasia (PPVH), and arteriovenous fistulas
were classified into the CCa group as this was the histological diagnosis.
The specific anomaly was recorded only when specified in the records.
Dogs with histological diagnosis of neoplasia were subclassified
into focal neoplasia, diffuse neoplasia, or metastatic neoplasia. Cases
with mesenchymal tumors, including hemangiosarcoma and poorly
differentiated sarcomas, cases with hepatocellular neoplasia, including
nodular hyperplasia, hepatocellular adenoma, hepatocellular carci-
noma, and unspecified hepatocellular epithelial tumor, and cases with
cholangiocellular tumors, including adenoma and carcinoma, were
placed into the focal neoplasia group. Dogs with round cell tumors,
including lymphoma, mast cell tumors, and unspecified type of round
cell tumor, were classified into the diffuse neoplasia group. Dogs that
had metastatic neuroendocrine tumors or metastatic adenocarci-
nomas were placed into the metastatic neoplasia group.
2.3 | Serum bile acids concentrations
Concentrations of SBAs were measured at 4 veterinary laboratories
(staffed by board-certified clinical pathologists), and all using commercially
available enzymatic spectrophotometric assays. The reagents used for
the determination of the SBA concentrations at the different diagnostic
laboratories were Randox (Randox Laboratories Ltd, Crumlin, United
Kingdom), Dialab (DIALAB GmbH, Wiener Neudorf, Austria), and Sentinel
(Sentinel Diagnostics, Milan, Italy). All 4 laboratories were members of an
external quality control scheme and ran daily quality control assessments.
The type of sample (resting and/or postprandial) was recorded.
The concentrations of resting and postprandial SBAs are presented as
median and range unless otherwise stated.
2.4 | Statistical analysis
Age data are presented as median, and sex information is presented
as the male to female (M : F) ratio for each liver disease.
Receiver operating characteristic (ROC) curve analysis (IBM SPSS
Version 24.0) was used to calculate the sensitivity and specificity of
resting and postprandial SBA concentrations for the diagnosis of each
individual liver disease, and all liver diseases combined. Dogs with RH
were used as the control group. Four different cut-off values (10, 30,
50, and 90 μmol/L) were evaluated. The 95% confidence interval
(CI) was also determined for each result.
The area under the ROC curve (AUC) was used to determine the
diagnostic performance of the tests for each disease. The diagnostic
performance was classified as high (0.9 < AUC < 1), moderate
(0.7 < AUC < 0.9), and low (0.5 < AUC < 0.7).6 The null hypothesis for
the ROC curve analysis is that the AUC is less or equal to 0.5.
The nonparametric Kruskal-Wallis test was used to evaluate if the
distribution of SBA concentrations measured with the different reagents
was statistically significant. The distribution of resting SBAs, measured
with each of the reagents, in each of the individual groups with number
of cases above 30 was also evaluated using the Kruskal-Wallis test.
3 | RESULTS
3.1 | Histopathology
Five dogs were excluded prior to analysis; 2 had nondiagnostic histo-
logical reports, 2 had a diagnosis which did not fit with the WSAVA
criteria, and 1 had a cholelith causing extrahepatic biliary obstruction.
Three hundred forty-one dogs met the inclusion criteria and the
histological diagnoses were as follows: AH (n = 12, 3.5%), cholangitis
(n = 21, 6.2%), CH (n = 92, 27%), CCa (n = 64, 18.8%), cirrhosis
(n = 4, 1.2%), miscellaneous (n = 4, 1.2%), neoplasia (n = 43, 12.6%),
RH (n = 76, 22.3%), and RHI (n = 25, 7.3%).
Dogs that were categorized into the miscellaneous group had
extramedullary hematopoiesis (n = 2) and hemosiderin accumula-
tion (n = 2).
Those 64 dogs classified into the group of CCa were diagnosed
with EHPSS (24/64, 37.5%), IHPSS (3/64, 4.7%), and PPVH (6/64,
9.4%). The type of vascular anomaly was not specified in the records
in 31 of 64 (48.4%) cases.
Dogs that were diagnosed with neoplasia had focal neoplasia
(n = 33), diffuse neoplasia (n = 6) and metastatic neoplasia (n = 4).
Those dogs with focal neoplasia were diagnosed with hem-
angiosarcoma (n = 2), poorly differentiated sarcoma (n = 1), nodular
hyperplasia (n = 3), hepatocellular adenoma (n = 6), hepatocellular car-
cinoma (n = 16), unspecified hepatocellular epithelial tumor (n = 3),
cholangiocellular adenoma (n = 1), and cholangiocellular carcinoma
(n = 1). Dogs with diffuse neoplasia were diagnosed with lymphoma
(n = 4), mast cell tumor (n = 1), and unspecified round cell tumor
(n = 1). Dogs with metastatic neoplasia were diagnosed with metastatic
neuroendocrine tumors (n = 3) and metastatic adenocarcinoma (n = 1).
3.2 | Sex and age distribution
The distribution of sex and age among the different groups is detailed in
Table 1. Of the total study sample, there were 195 males (57%) and
146 females (43%). Dogs with RHI had the highest M : F ratio (M : F
ratio = 3.17), followed by RH (M : F ratio = 1.53), CCa (M : F ratio = 1.37),
CH (M : F ratio = 1.24), neoplasia (M : F ratio = 1.05), cirrhosis (M : F
ratio= 1), cholangitis (M : F ratio= 0.91), and AH (M : F ratio= 0.5).
The median age (years) for the different groups was distributed as
follows: neoplasia (10), cholangitis (9), CH, cirrhosis, RH and RHI (7),
and AH (4.96). Congenital circulatory anomalies were diagnosed more
frequently in younger dogs, with a median age of 1.9 years.
3.3 | Serum bile acids
Resting SBA concentrations were available in 337/341 (98.8%) dogs,
and the postprandial value was available in 151/341 (44.3%) cases.
The median and range concentrations of resting and postprandial
SBA concentrations for each disease are displayed in Table 2. The
median resting SBA concentrations was highest in cirrhosis
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(98.8 μmol/L) followed by CCa (79.45 μmol/L), cholangitis (48 μmol/
L), CH (41.85 μmol/L), AH (24.55 μmol/L), RHI (15 μmol/L), neoplasia
(11.7 μmol/L), and RH (10 μmol/L).
The median postprandial SBA concentrations were highest in CCa
(126 μmol/L) followed by CH (54.3 μmol/L), cholangitis (54 μmol/L),
RHI (45 μmol/L) cirrhosis (43 μmol/L), RH (39 μmol/L), neoplasia
(22 μmol/L), and AH (4.15 μmol/L).
Resting SBAs were available in 32 out of 33 dogs with focal neo-
plasia (median 9.5 μmol/L, range, 1-381 μmol/L), all 6 dogs with dif-
fuse neoplasia (median 30.5 μmol/L, range, 9-49.3 μmol/L), and all
4 dogs with metastatic neoplasia (median 15 μmol/L, range,
1-30 μmol/L). Postprandial SBAs were available in 10 out of 33 dogs
with focal neoplasia (median 21.35 μmol/L, range, 5-868 μmol/L),
none of the dogs with diffuse neoplasia, and 1 dog out of 6 with met-
astatic neoplasia (52 μmol/L).
A bile acid stimulation test was performed in 147 dogs (43.1%). In
27.2% of the cases (40/147), the postprandial value was lower than the
resting value. This was found in cholangitis (3 out of 5 dogs, 60.0%),
cirrhosis (1 out of 3, 33.3%), CH (11 out of 34, 32.4%), RH (9 out of
36, 25.0%), CCa (11 of 45, 24.4%), RHI (2 out of 10, 20.0%), and neo-
plasia (1 out of 10, 10.0%). Postprandial SBAs were lower than resting
SBAs in both dogs with miscellaneous diseases, and in none of the
2 dogs with AH who had the bile acid stimulation test performed.
3.4 | Sensitivity, specificity, and diagnostic
performance
The sensitivities of resting and postprandial SBA concentrations for
each disease using the different cut-off values are shown in Table 3.
The highest sensitivities of resting SBAs using the cut-off value of
10 μmol/L were recorded in CCa (87.5%), cholangitis (85.7%), and CH
(81.1%). When the cut-off values used were increased to 30, 50, and
90 μmol/L the highest sensitivities of resting SBAs were recorded in
cirrhosis (75%, 75%, and 50%, respectively), CCa (70.3%, 64.1%, and
45.3%, respectively), and CH (56.7%, 41.1%, and 23.3% respectively).














Median age in years
(range)
Acute hepatitis 12 3 5 0 4 0.5 4.96 (0.25-11.17)
Cholangitis 21 2 9 1 9 0.91 9 (4.83-15)
Chronic hepatitis 92 9 32 10 41 1.24 7 (0.33-15)
Cirrhosis 4 0 2 1 1 1 7 (5–9)
Congenital circulatory
anomaly
64 14 13 18 19 1.37 1.9 (0.33-8.17)
Miscellaneous 4 0 0 1 3 N/a 6.5 (5-9.83)
Neoplasia 43 1 20 6 16 1.05 10 (2.25-15.17)
Reactive hepatitis 76 8 22 15 31 1.53 7 (0.25-16)
Reversible hepatocytic
injury
25 3 3 4 15 3.17 7 (0.33-14)
Notes: Age is expressed in years.
TABLE 2 Serum bile acid concentrations in dogs with different liver diseases












































































Abbreviations: AH, acute hepatitis; CCa, congenital circulatory anomaly; CH, chronic hepatitis; Miscell., miscellaneous; RH, nonspecific reactive hepatitis;
RHI, reversible hepatocytic injury.
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The highest sensitivities of postprandial SBAs using the cut-off
value of 10 μmol/L were recorded in cholangitis (100%), CCa (91.1%),
and CH (75.0%). When the cut-off values used were increased to
30 μmol/L, the highest sensitivities were seen in CCa (86.7%), cirrho-
sis (66.7%) and RHI and cholangitis (both 60.0%). Using the cut-off
value of 50 μmol/L, the sensitivities of SBAs were higher in CCa
(80.0%), cholangitis (60.0%), and CH (52.8%). Finally, the highest sen-
sitivities using the cut-off value of 90 μmol/L were found in CCa
(68.9%), cholangitis (40%), and cirrhosis (33.3%).
Combining all diseases together, the sensitivities of resting SBAs
for the diagnosis of liver disease using the cut-off values of 10, 30,
50, and 90 μmol/L were 75.6% (95% CI 69.9-80.7), 49.2% (95% CI
43.0-55.5), 38.6% (95% CI 32.6-44.7), and 24.4% (95% CI 19.3-30.1),
respectively. The sensitivities of postprandial SBAs using the same
cut-off values were 81.6% (95% CI 73.2-88.2), 64.9% (95% CI
55.4-73.6), 59.6% (95% CI 50.0-68.7), and 44.7% (95% CI 35.4-54.3),
respectively.
The specificities of resting SBAs for the diagnosis of liver disease
using the cut-off values of 10, 30, 50 and 90 μmol/L were 49.3%
(95% CI 37.6-61.1), 73.3% (95% CI 61.9-82.9), 82.7% (95% CI
72.2-90.4), and 94.7% (95% CI 86.9-98.5), respectively. The specific-
ities of postprandial SBAs for the diagnosis of liver disease using the
same cut-off values were 29.7% (95% CI 15.9-47.0), 43.2% (95% CI
27.1-60.5), 59.5% (95% CI 42.1-75.2), and 83.8% (95% CI 68.0-93.8),
respectively.
The AUC demonstrated that the measurement of resting SBAs
has a moderate diagnostic performance for the diagnosis of cirrhosis
(0.80), CCa (0.80), CH (0.73), and cholangitis (0.75). Postprandial SBAs
also showed moderate diagnostic performance for the diagnosis of
CCa (0.80). The diagnostic performance of resting SBAs was low for
the diagnosis of AH (0.63), RHI (0.55), and neoplasia (0.53). Postpran-
dial SBAs showed low diagnostic performance for the diagnosis of
cholangitis (0.66), cirrhosis (0.61), CH (0.58), and RHI (0.55) (Table 4).
The nonparametric Kruskal-Wallis test showed that the distribu-
tion of SBA concentrations was not significantly different across the 3
groups (reagents) (P = .77). The resting SBA concentrations, of all
dogs included in the study, obtained with each of the reagents are dis-
played in Supporting Information Figure S1. The distribution of resting
SBAs, measured with each of the reagents, in each of the individual
groups with number of cases above 30 (CH, RH, CCa, and neoplasia)
was also not significantly different (P = .53, P = .07, P = .39, and
P = 1.000, respectively). The resting SBA concentrations of each of
these individual groups, measured with the different reagents, are also
displayed in Supporting Information Figures S2–S5.
4 | DISCUSSION
This multicenter retrospective study documents the concentrations of
SBAs in liver diseases diagnosed according to WSAVA Liver Standard-
ization Group. Moreover, this study to reports the sensitivity and
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This study documents overlap between SBAs, both resting and
postprandial values, in different liver diseases in dogs, thereby limiting
the utility of a single SBAs measurement as a test to differentiate
between liver diseases. Resting SBAs below 10 μmol/L do not exclude
liver disease being present, and moreover values above 90 μmol/L can
be seen in dogs without liver disease. Furthermore, postprandial SBAs
below 10 μmol/L occur in diseases in which elevated postprandial
SBAs might be expected, such as CCa, CH, and cirrhosis.
In this study, the sensitivities of postprandial SBA concentrations
for the diagnosis of liver disease were higher than resting SBAs using
the different cut-off values. Resting SBAs had higher specificities than
postprandial SBAs when the same cut-off values were used. There-
fore, compared with resting SBAs, postprandial SBAs might be a more
suitable screening test to exclude liver disease although, in our study,
18.4% of dogs with liver disease had postprandial values below
10 μmol/L and 35.1% below 30 μmol/L.
Using a cut-off value of 10 μmol/L, the sensitivity of resting SBA
concentrations for the diagnosis of AH was 58.3%, which contrasts to
15% previously reported.7 Using the same cut-off value, the sensitivi-
ties of resting and postprandial SBA concentrations for CH were
81.1% and 75%, respectively; however, these were below 60% when
increasing the cut-off to 30 μmol/L. Similarly, concentrations of SBAs
have been described as the most sensitive marker of CH, with sensi-
tivities reported to be 61% to 89%, but values within the reference
intervals can be found in early disease.8 Damage of the hepatocytes
might lead to reduced functional hepatic mass which impairs the
clearance of bile acids from the portal blood.1 It is therefore expected
that dogs with AH, CH and cirrhosis can present with reduced func-
tion as well as intrahepatic cholestasis, both factors contributing to
the increase in SBAs.9 Depending on the degree of hepatocellular
damage, the associated increase in SBAs can be variable, and we
hypothesize that it is likely to be proportional to the amount of hepa-
tocyte loss and the degree of cholestasis that occurs secondary to the
hepatocellular damage.
In this study, resting SBAs were increased in 87.5%, 70.3%, and
64.1% of dogs with CCa using the cut-off values of 10, 30,
and 50, respectively. These results are similar to those of previous
studies which reported sensitivities of 87.1% to 98%, 70.5%, and
62.9%, respectively when using the same cut-off values.10,11 The
abovementioned studies included dogs with EHPSS, IHPSS, PPVH
and arteriovenous fistulas;10 however, there were also some dogs
included with acquired portosystemic shunts secondary to chronic
hepatitis or cirrhosis.11 Due to the different conditions classified as
circulatory abnormalities in these studies, we acknowledge that the
data from our study might not be directly comparable. In our study,
we included 64 dogs with a histological diagnosis of CCa, but in 31 of
these the specific type of vascular anomaly was not identified by the
referral center. Consequently, we were not able to subclassify these
cases further. It is therefore possible that some of the 31 dogs had
arteriovenous fistulas, as well as PPVH or intrahepatic/extrahepatic
shunts. In the group of dogs with CCa, the median concentrations of
postprandial SBAs was the highest of all diseases (126 μmol/L), with
31 out of 45 dogs (68.9%) having SBAs above 90 μmol/L. In previous
studies, the median values of postprandial SBAs were reported to be
between 113 and 229.9 μmol/L.2,12-14 100% of 19 dogs with congeni-
tal portosystemic shunt (cPSS) have postprandial SBAs above
43 μmol/L, reflecting the high sensitivity of postprandial SBAs for the
diagnosis of CCa.13 In the aforementioned study, there was no cross-
over between healthy dogs and dogs with cPSS, suggesting postpran-
dial SBAs could be used to rule out cPSS using a cut-off value of
30 μmol/L.13 However, in our study we found that 4 out of 45 cases
(8.9%) with CCa had postprandial SBAs below 10 μmol/L, 6 out of
45 cases (13.3%) had values below 30 μmol/L, and 9 dogs (20%) had
values below 50 μmol/L. These results highlight that not all dogs with
circulatory anomalies of the liver have increased postprandial SBAs.
The maximum concentration of SBAs might not always occur 2 hours
after a meal, as factors like responsiveness of the gallbladder to chole-
cystokinin or the intestinal transit time can affect this. Consequently,
even though it is a sensitive test, 2-hour postprandial SBAs below
10 μmol/L can be found in dogs with CCa.
The term RHI is used to describe a group of hepatopathies that
result from the reversible accumulation of water, glycogen, or fat in
the cytoplasm of the hepatocytes.15 This study documented that
4 out of 25 (16%) and 5 out of 10 (50%) dogs with RHI had resting
and postprandial SBA concentrations above 50 μmol/L, respectively.
These results contrast previous data, in which glucocorticoid
hepatopathy, a type of RHI, was associated with normal to mildly
increased SBAs, with an elevation of up 58 μmol/L in 1 study.2
TABLE 4 Diagnostic performance of serum bile acids was determined using the area under the receiver operating characteristic curve
Histological diagnosis n (resting SBAs) AUC (95% CI) n (postprandial SBAs) AUC (95% CI)
Acute hepatitis 12 0.63 (0.46-0.81) 2 0.22 (0.08-0.35)
Cholangitis 21 0.75 (0.63-0.87) 5 0.66 (0.43-0.88)
Chronic hepatitis 90 0.73 (0.66-0.81) 36 0.582 (0.45-0.71)
Cirrhosis 4 0.80 (0.58-1) 3 0.61 (0.27-0.95)
Congenital circulatory anomaly 64 0.80 (0.72-0.87) 45 0.80 (0.70-0.89)
Neoplasia 42 0.53 (0.43-0.64) 11 0.46 (0.29-0.64)
Reversible hepatocytic injury 25 0.55 (0.43-0.68) 10 0.55 (0.33-0.77)
Notes: The diagnostic performance was classified as high (0.9 < AUC < 1), moderate (0.7 < AUC < 0.9), and low (0.5 < AUC < 0.7).
Abbreviations: AUC, area under the curve; CI, confidence interval; SBAs, serum bile acids.
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Because the liver function in dogs with RHI is thought to remain unaf-
fected, it is likely that the increase in SBAs is a consequence of bile
stasis secondary to hepatocyte swelling.16 The results of our study
suggest that the degree of cholestasis associated with this disease
should not be underestimated, and could be clinically significant.
Moreover, there was considerable overlap between SBA concentra-
tions of dogs with RHI and dogs with diseases of known clinical signif-
icance (ie, CCa, CH, and cholangitis). Thus, RHI should be considered a
differential diagnosis in a dog with suspected liver disease presenting
with high SBAs.
Cholangitis is a nonobstructive inflammatory disorder that affects
the intrahepatic biliary ducts.3,16 The inflammation is diffuse and tar-
gets the biliary tree, leading to intrahepatic cholestasis.9 Concentra-
tions of SBAs have not previously been evaluated in dogs with
cholangitis. Three out of 21 dogs (14.3%) in the present study had
resting SBAs below 10 μmol/L, but postprandial values were consider-
ably higher, with all 5 dogs having values above 25 μmol/L. Interest-
ingly, of the 5 dogs with cholangitis which had both resting and
postprandial SBAs measured, none had a marked increase of SBAs in
the postprandial sample compared to the resting sample. Three of
those 5 dogs had lower postprandial SBA concentrations compared to
the resting SBAs. The other 2 dogs had less than 2-fold increase of
SBAs postprandially. We hypothesize that the lack of an increase in
SBAs might be the result of an ineffective or slowed transportation of
bile from the biliary system into the duodenum as a consequence
of the inflammation of the biliary epithelium. Consequently, the pool
of bile acids in the portal blood flow might not be significantly
increased 2 hours after the ingestion of the meal, limiting the increase
of concentrations of postprandial SBAs in the systemic circulation
compared to the resting concentrations.
The specificities of SBAs for the diagnosis of liver disease were
considerably lower than previously reported.2,5 Using a cut-off value
of 10 μmol/L, resting and postprandial SBAs had a specificity of
49.3% and 29.7%, respectively. The specificities increased to 82.7%
and 59.5%, respectively when using the cut-off value of 50 μmol/L.
This contrasts with previous studies, in which resting and postprandial
SBA concentrations were reported to have a specificity of 100% using
the cut-off values of 20 and 25 μmol/L, respectively.2,5 The specificity
of a test will vary depending on the cohort of dogs used in the control
group. The control group used in our study comprised dogs with
suspected liver disease and histological features consistent with RH,
and this approach has been used in previous studies.2,5 The authors of
the present study conclude that the use of dogs with RH is the most
optimal available option as those represent a sample of dogs that have
clinical and clinicopathological characteristics similar to the diseased
group, but histological changes suggestive of an extrahepatic cause.
The clinical presentation of dogs with CCa is usually different than the
presentation of dogs with RH, hence this might not be the optimal
control for the CCa group. Ideally, a control group should consist of
healthy dogs with no abnormalities on liver histology. However, it is
very uncommon to identify such dogs as samples of liver tissues are
usually taken because of clinical suspicion of liver disease, especially if
the serum liver enzyme activities are increased. In addition, the use of
a control group comprised of dogs with suspected liver disease makes
the specificities more relevant as they relate to the sample of dogs in
which a liver biopsy could be taken, due to the clinical suspicion of
liver disease.
Approximately one quarter (27.2%) of the dogs that underwent
bile acid stimulation test had lower concentrations of postprandial
SBAs than resting SBAs, which is similar to a previous report.2 It has
been suggested that this can be related to individual variations in gas-
tric emptying, cholecystokinin response, intestinal transit time or
intestinal absorption.16,17 It could be that, in some cases, stimulation
of the gallbladder contraction did not occur after the ingestion of the
meal, or the peak of postprandial SBAs happened more than 2 hours
after the release of cholecystokinin. This finding, however, is a possi-
ble limitation of the study, as the peak of postprandial SBAs of these
dogs could have been missed and the obtained value could have been
an underestimation.
The retrospective nature of this study means there were several
additional limitations. We were unable to confirm if all patients had
been starved sufficiently prior to measurement of resting SBA con-
centrations, which could have resulted in increased resting SBAs in
the absence of liver disease. Unfortunately, another limitation was
that we were not able to determine if the bile acid stimulation test
was performed correctly, and it might be that some dogs did not eat
an adequate amount or type of food to stimulate gallbladder contrac-
tion, thus affecting the concentrations of postprandial SBAs. Further-
more, SBA concentrations were measured in 4 different referral
laboratories, using 3 different enzymatic spectrophotometric
methods, which is likely to have increased the variability of our data;
however, we would expect this limitation to decrease the calculated
sensitivity and specificity values, therefore our data will still reflect
minimum values for these parameters. Although the reference inter-
vals reported by the different laboratories did vary, the vast majority
of reference laboratories in the United Kingdom are unable to derive
their own reference intervals for SBA concentrations due to lack of
access to samples from a suitable number (>40) of healthy animals,
because sampling of healthy animals cannot be performed in the
United Kingdom on ethical grounds. Therefore many laboratories will
adopt the reference intervals from other laboratories or from the liter-
ature, and they subsequently verify these intervals in their own labo-
ratories using a smaller number of apparently healthy animals, to
ensure that 95% of the values obtained in these animals fall within
the adopted reference interval (reference interval transference).18 The
disadvantage of this approach is that the limits of the reference inter-
val might be inaccurate, particularly given the variability that occurs
between laboratories. Therefore, although comparison of the absolute
SBA concentrations between different laboratories is not ideal, com-
parison of the bile acid concentrations normalized to the upper limit
of the laboratory specific reference intervals would be unlikely to
yield an improvement in the calculated sensitivity and specificity
values. Moreover, many small animal veterinarians are using referral
laboratories to measure SBA, and these laboratories could also use
reference intervals adopted from the literature, or from other labora-
tories. Consequently, veterinarians will not be able to apply the values
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normalized to the upper limit to their clinical practice. Furthermore,
we anticipate that the biological variation of SBA in dogs is high com-
pared to other biochemical analytes, as it has been shown in other
species.19,20 This can be due to diurnal rhythms of bile acid synthesis,
spontaneous contraction of the gall bladder and variations in intestinal
motility, among other factors. The biological variation of bile acids is
likely to have significantly greater impact on the bile acid concentra-
tions measured than the impact of the use of these different reagents.
The Kruskal-Wallis test is a nonparametric analysis of variance that
was used in our study to prove the hypothesis that the BAs measured
with the 3 different reagents do not differ and are therefore directly
comparable, allowing the combination of the SBA concentration
values obtained with the 3 reagents, and the use of the different
absolute cut-off values. In addition, most histological samples were
only reviewed by 1 board certified pathologist, although they were all
done so using published WSAVA criteria. However, we acknowledge
that it is possible that some samples could have been misclassified. In
addition, although the total number of cases in this study was very
large, there were relatively small numbers of cases in certain individual
diseases, thereby limiting conclusions that can be drawn. Further
studies could aim to collect data from larger numbers of dogs with
these diseases. Serum bilirubin concentrations, or the clinical sign of
icterus, were not recorded by all centers, therefore these were not
exclusion criteria. In our study, as the cases were from Specialist-lead
referral centers, it is likely that dogs with icterus or elevated serum bil-
irubin did not have postprandial SBAs measured. However, SBAs are
often included in routine biochemistry profiles, and consequently rest-
ing SBAs might have been measured, thus some dogs included might
have had concurrent elevation of SBAs and bilirubin. Finally, all dogs
in the study had suspected liver disease before the biopsy was taken,
and for this reason, this could have resulted in the inclusion of dogs
with more accentuated elevation of SBAs, not being a true represen-
tation of all dogs with liver disease.
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